abstract |
1. The use of the peptide His-Pro-Gly-Ser-Arg-Ile-Val-Leu-Ser-Leu-Asp-Val-Pro-Ile-Gly-Leu-Leu-Gln-Ile-Leu-Leu-Glu-Gln- Ala-Arg-Ala-Arg-Ala-Ala-Arg-Glu-Gln-Ala-Thr-Thr-Asn-Ala-Arg-Ile-Leu-Ala-Arg-Val-NH2 to obtain a pharmaceutical composition for treatment and / or prevention of malignant tumors, autoimmune diseases, fibrosis, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and blood vessel diseases and metabolic diseases. ! 2. The use of the peptide according to claim 1, where the malignant tumor, autoimmune disease, fibrosis, inflammatory disease, neurodegenerative disease, infectious disease, lung disease, heart and vascular disease or metabolic disease are selected from vasculitis and excessive angiogenesis in autoimmune diseases, systemic sclerosis , multiple sclerosis, Sjogren's syndrome, vascular deformities in the networks of blood and lymph vessels, DiGeorge syndrome, congenital hemorrhagic telangiectasia, cavernous heme ngiomas, cutaneous hemangiomas, lymphatic vessel deformities, graft arteriopathies, atherosclerosis, vascular anastomoses, adipose tissue for obesity, chronic allograft rejection, skin diseases, psoriasis, papillomas, allergic dermatitis, keloid scars, pyogenic granulomas, ulcer patients, AIDS, systemic sclerosis, eye diseases, persistent vitreous hyperplastic syndrome, diabetic retinopathy, premature retinopathy, neovascularization of the choroid eye, lung diseases, pulmonary hypertension, asthma, nasal polyps, rhinitis, chronic inflammation and obstruction of the stomach |